Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide, today announced that it will be presenting in person at the 17th annual BIO-Europe Spring taking place March 20-22, 2023 in Basel, Switzerland.
Elpiscience has been focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. Darren Ji, Co-founder and CEO of Elpiscience, will present the company’s core pipeline programs including its Phase 1 欧洲杯买球网游戏, a first-in-class anti-CD39/TGF-β bispecific antibody that is expected of having single agent anti-tumor activity, a highly differentiated anti-LILRB2 antibody 欧洲杯买球网棋牌 that effectively reprogram macrophage from M2 to M1, and a pan-acting anti-SIPRα antibody ES004 with a larger population coverage.
Darren Ji will also join a panel to discuss the involving APAC partnering paradigms on March 21，2023 during the event.
Presentation schedule:
- Date and Time: March 20th, 13:00-13:15 (CET)
- Presenter: Darren Ji, Co-Founder and CEO of Elpiscience
- Venue: Room 2, Messe Basel, Basel, Switzerland
Panel schedule:
- Panel Discussion: APAC partnering: where are we and where does the future lie?
- Panelist: Darren Ji, Co-Founder and CEO of Elpiscience
- Date and Time: March 21st, 10:30 - 11:15 (CET)
- Venue: Room 1, Messe Basel, Basel, Switzerland
About Elpiscience
Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.
Corporate Communications:
PR@elpiscience.com
Partnering:
BD@elpiscience.com
